
## **Christian Schulz**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8062679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New Rapid Helicobacter Pylori Blood Test Based on Dual Detection of FliD and CagA Antibodies for On-Site Testing. Clinical Gastroenterology and Hepatology, 2023, 21, 229-231.e1.	2.4	6
2	Biliary Cannulation in Endoscopic Retrograde Cholangiography: How to Tackle the Difficult Papilla. Digestive Diseases, 2022, 40, 85-96.	0.8	8
3	The Fear of Gastric Cancer in Patients with Dyspepsia: Challenge in Specialist Care Gastroenterology. Digestive Diseases, 2022, 40, 409-416.	0.8	2
4	<b><i>Helicobacter pylori</i></b> Infection in Africa: Update of the Current Situation and Challenges. Digestive Diseases, 2022, 40, 535-544.	0.8	21
5	Current State of Multidisciplinary Treatment in Cholangiocarcinoma. Digestive Diseases, 2022, 40, 581-595.	0.8	7
6	Deep learning in CT colonography: differentiating premalignant from benign colorectal polyps. European Radiology, 2022, 32, 4749-4759.	2.3	12
7	Influence of COVID-19 Pandemic on Endoscopic Procedures in Two European Large-Capacity Endoscopy Units: "Keep Calm, Keep Safe and Scope on?― Digestive Diseases, 2021, 39, 540-548.	0.8	10
8	Prevalence, Resistance Rates, and Risk Factors of Pathogens in Routine Bile Cultures Obtained during Endoscopic Retrograde Cholangiography. Digestive Diseases, 2021, 39, 42-51.	0.8	13
9	Impact of healthy aging on active bacterial assemblages throughout the gastrointestinal tract. Gut Microbes, 2021, 13, 1966261.	4.3	7
10	Machine Learning–based Differentiation of Benign and Premalignant Colorectal Polyps Detected with CT Colonography in an Asymptomatic Screening Population: A Proof-of-Concept Study. Radiology, 2021, 299, 326-335.	3.6	30
11	Gut microbiota profiles and the role of antiâ€CdtB and antiâ€vinculin antibodies in patients with functional gastrointestinal disorders (FGID). European Journal of Clinical Investigation, 2021, 51, e13666.	1.7	10
12	Peptic Ulcer: Chapter Closed?. Digestive Diseases, 2020, 38, 112-116.	0.8	25
13	Prevalence of Helicobacter pylori Infection in Patients with Minimal Hepatic Encephalopathy. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 191-195.	0.5	9
14	Superiority of a Split-dose Regimen of Sodium Picosulfate/ Magnesium Citrate (SPMC) in Comparison to a Prior-day Schedule (AM/PM) for Colonoscopy Preparation. A Randomized Single-blinded Study. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 295-302.	0.5	7
15	Reply. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 406-7.	0.5	О
16	Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology, 2019, 157, 1081-1092.e3.	0.6	103
17	Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps. Nature Communications, 2019, 10, 2273.	5.8	94
18	What is the Relevance of Gastric Microbiota Beyond H. pylori?. Current Treatment Options in Gastroenterology, 2019, 17, 619-627.	0.3	4

CHRISTIAN SCHULZ

#	Article	IF	CITATIONS
19	The role of the gastric bacterial microbiome in gastric cancer: <i>Helicobacter pylori</i> and beyond. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989406.	1.4	54
20	Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy. Digestive Diseases, 2019, 37, 161-169.	0.8	19
21	Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2018, 24, 1547-1557.	0.9	92
22	Expression of microRNAs in the ascites of patients with peritoneal carcinomatosis and peritonitis. Cancer Cytopathology, 2018, 126, 353-363.	1.4	13
23	The active bacterial assemblages of the upper GI tract in individuals with and without <i>Helicobacter</i> infection. Gut, 2018, 67, 216-225.	6.1	151
24	Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clinical and Experimental Gastroenterology, 2016, 9, 97.	1.0	47
25	<b><i>Helicobacter pylori</i></b> and Other Gastric Microbiota in Gastroduodenal Pathologies. Digestive Diseases, 2016, 34, 210-216.	0.8	45
26	Endoscopic peroral jejunal fecal microbiota transplantation. Digestive and Liver Disease, 2016, 48, 1336-1339.	0.4	24
27	Other Helicobacters and gastric microbiota. Helicobacter, 2016, 21, 62-68.	1.6	24
28	RiMINI – the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Trials, 2016, 17, 111.	0.7	14
29	Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clinical Nutrition, 2015, 34, 1122-1127.	2.3	98
30	Nutrition and Hepatocellular Cancer. Gastrointestinal Tumors, 2015, 2, 188-194.	0.3	33
31	Does H. pylori Eradication Therapy Benefit Patients With Hepatic Encephalopathy?. Journal of Clinical Gastroenterology, 2014, 48, 491-499.	1.1	20
32	Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World Journal of Hepatology, 2014, 7, 139.	0.8	72
33	Doubleâ€balloon enteroscopy in the diagnosis of suspected isolated <scp>C</scp> rohn's disease of the small bowel. Digestive Endoscopy, 2014, 26, 236-242.	1.3	29
34	Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. Gastrointestinal Tumors, 2014, 1, 84-92.	0.3	19